Allergy: A risk factor for suicide?

Current Treatment Options in Neurology

Volumn 10, Issue 5, 2008, Pages 363-376

  Postolache, Teodor T ^a   Komarow, Hirsh ^a   Tonelli, Leonardo H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; HYDROXYZINE; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 2; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MOMETASONE FUROATE; MONTELUKAST; NASACORT AQ; NEDOCROMIL SODIUM; OXEDRINE; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ZAFIRLUKAST; ZILEUTON;

AGGRESSION; AGITATION; ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANXIETY; BEDTIME DOSAGE; CELLULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HEALTH CARE COST; HEPATITIS C; HOPELESSNESS; HOSTILITY; HUMAN; IMMUNOTHERAPY; INCIDENCE; INSOMNIA; INTRACUTANEOUS TEST; LAVAGE; MANIA; MELANOMA; MIGRAINE; MIXED MANIA AND DEPRESSION; MOUTH DISEASE; NERVOUSNESS; NONHUMAN; NOSE CONGESTION; ORBITAL CORTEX; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PREFRONTAL CORTEX; PRICK TEST; PSYCHOSIS; RESTLESSNESS; REVIEW; RISK FACTOR; SEASONAL VARIATION; SEDATION; SEIZURE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPRING; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYSTEMIC DISEASE; TH2 CELL; THROAT IRRITATION; TONGUE SWELLING; UNSPECIFIED SIDE EFFECT; URTICARIA;

EID: 58649105352     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0039-4     Document Type: Review

References (103)

1. Mann JJ: Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003, 4:819-828.
2. Goodwin FK, Jamison KR: Manic Depressive Illness: Bipolar Disorders and Recurrent Depression, edn 2. New York: Oxford University Press; 2007.
3. American Academy of Allergy Asthma & Immunology: National Allergy Bureau. Available at http://www.aaaai.org/nab/index.cfm. Accessed June 19, 2008.
4. Kosisky SE, Carpenter GB: Predominant tree aeroallergens of the Washington, DC area: A six year survey (1989-1994) Ann Allergy Asthma Immunol 1997, 78:381-392.
5. Postolache TT, Stiller JW, Herrell R, et al.: Tree pollen peaks are associated with increased nonviolent suicide in women. Mol Psychiatry 2005, 10:232-235.
6. Timonen M, JokelRinen J, Hakko H, et al.: Atopy and depression: results from the Northern Finland 1966 Birth Cohort Study. Mol Psychiatry 2003, 8:738-744.
7. Marshall PS, O'Hara C, Steinberg P: Effects of seasonal allergic rhinitis on fatigue levels and mood. Psychosom Med 2002, 64:684-691.
8. Guzman A, Tonelli LH, Roberts D, et al.: Mood-worsening with high-pollen-counts and seasonality: A preliminary report. J Affect Disord 2007, 101:269-274.
9. Postolache TT, Lapidus M, Sander ER, et al.: Changes in allergy symptoms and depression scores are positively correlated in patients with recurrent mood disorders exposed to seasonal peaks in aeroallergens. ScientificWorldJournal 2007, 7:1968-1977.
10. Postolache TT, Langenberg PB, Zimmerman SA, et al.: Changes in severity of allergy and anxiety symptoms are positively correlated in patients with recurrent mood disorders who are exposed to seasonal peaks of aeroallergens. Int J Child Health Hum Dev (in press).
11. Bell IR, Jasnoski MLS Kagan J, et al.: Depression and allergies: survey of a nonclinical population. Psychother Psychosom 1991, 55:24-31.
12. Hashiro M, Okumura M: The relationship between the psychological and immunological state in patients with atopic dermatitis. J Dermatol Sci 1998, 16:231-235.
13. Timonen M, Jokelainen J, Silvennoinen-Kassinen S, et al.: Association between skin test diagnosed atopy and professionally diagnosed depression: A Northern Finland 1966 Birth Cohort study. Biol Psychiatry 2002, 52:349-355.
14. Timonen M, Jokelainen J, Herva A, et al.: Presence of atopy in first-degree relatives as a predictor of a female proband's depression: results from the Northern Finland 1966 Birth Cohort. J Allergy Clin Immunol 2003, 111:1249-1254.
15. Wamboldt MZ, Hewitt JK, Schmitz S, et al.: Familial association between allergic disorders and depression in adult Finnish twins. Am J Med Genet 2000, 96:146-153.
16. Wilken JA, Berkowitz R, Kane R: Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2002, 89:372-380.
17. Hurwitz EL, Morgenstern H: Cross-sectional associations of asthma, hay fever, and other allergies with major depression and low-back pain among adults aged 20-39 years in the United States. Am J Epidemiol 1999, 150:1107-1116.
18. Addolorato G, Ancona C, Capristo E, et al.: State and trait anxiety in women affected by allergic and vasomotor rhinitis. J Psychosom Res 1999, 46:283-289.
19. Prolo P, Licinio J: Cytokines in affective disorders and schizophrenia: new clinical and genetic findings. Mol Psychiatry 1999, 4:396.
20. Capuron L, Ravaud A, Gualde N, et al.: Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001, 26:797-808.
21. Dantzer R, Wollman EA, Yirmiya R: Cytokines and depression: an update. Brain Behav Immun 2002, 16:501-502.
22. Capuron L, Dantzer RT Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003, 17(Suppl 1):S119-S124.
23. Anisman H, Merali Z, Poulter MO, et al.: Cytokines as a precipitant of depressive illness: Animal and human studies. Curr Pharm Des 2005, 11:963-972.
24. Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:201-217.
25. Raison CL, Capuron LI Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24-31.
26. Dantzer R, Kelley KW: Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007, 21:153-160.
27. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000, 157:867-876.
28. Crone CC, Gabriel GM, Wise TN: Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med 2004, 71(Suppl 3):S27-S32.
29. Raison CL, Demetrashvili M, Capuron L, et al.: Neuropsychiatric adverse effects of interferon-alpha: Recognition and management. CNS Drugs 2005, 19:105-123.
30. Denicoff KD, Rubinow DR, Papa MZ, et al.: The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987, 107:293-300.
31. Capuron L, Ravaud A, Dantzer R: Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 2000, 18:2143-2151.
32. Capuron L, Dantzer R, Miller AH: Neuro-immune interactions in psychopathology with the example of interferon alpha-induced depression. J Soc Biol 2003, 197:151-156.
33. Frommberger UH, Bauer J, Haselbauer P, et al.: Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997, 247:228-233.
34. Levine J, Barak Y, Chengappa KN, et al.: Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999, 40:171-176.
35. Yirmiya R, Weidenfeld J, Pollack Y, et al.: Cytokines, "depression due to a general medical condition," and antidepressant drugs. Adv Exp Med Biol 1999, 461:283-316.
36. Dunn AJ, Swiergiel AH, de Beaurepaire R: Cytokines as mediators of depression: What can we learn from animal studies? Neurosci Biobehav Rev 2005, 29:891-909.
37. Dunn AJ, Swiergiel AH: Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacol Biochem Behav 2005, 81:688-693.
38. Swiergiel AH, Dunn AJ: Effects of interleukin-1beta and lipopolysaccharide on behavior of mice in the elevated plusmaze and open field tests. Pharmacol Biochem Behav 2007, 86:651-659.
39. Reichenberg A, Yirmiya R, Schuld A, et al.: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001, 58:445-452.
40. De La Garza R: Endotoxin-or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: Focus on anhedonia. Neurosci Biobehav Rev 2005, 29:761-770.
41. Engeland CG, Kavaliers M, Ossenkopp KP: Sex differences in the effects of muramyl dipeptide and lipopolysaccharide on locomotor activity and the development of behavioral tolerance in rats. Pharmacol Biochem Behav 2003, 74:433-447.
42. Tonelli LH, Stiller J, Rujescu D, et al.: Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 2008, 117:198-206.
43. Tonelli LH, Holmes A, Postolache TT: Intranasal immune challenge induces sex-dependent depressive-like behavior and cytokine expression in the brain. Neuropsychopharmacology 2008, 33:1038-1048.
44. Tonelli LH, Virk G, Joppy B, et al.: Experimentally induced allergy to tree pollen induces depressive-like behavior and mast cell activation in the brain of female rats. Society of Biological Psychiatry Annual Meeting, Toronto, Canada; 2006.
45. Tonelli LH, Hoshino A, Katz M, et al.: Acute stress promotes aggressive-like behavior in rats made allergic to tree pollen. Int J Child Health Hum Dev (in press).
46. Goehler LE, Gaykema RP, Hansen MK, et al.: Vagal immune-to-brain communication: A visceral chemosensory pathway. Auton Neurosci 2000, 85:49-59.
47. Quan N, Herkenham M: ConneAting cytokines and brain: a review of current issues. Histol Histopathol 2002, 17:273-288.
48. Pitossi F, del Ray A, Kabiersch A, et al.: Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J Neurosci Res 1997, 48:287-298.
49. Molina-Holgado F, Toulmond S, Rothwell NJ: Involvement of interleukin-1 in glial responses to lipopolysaccharide: Endogenous versus exogenous interleukin-1 actions. J Neuroimmunol 2000, 111:1-9.
50. Turrin NP, Plata-Salamán CR: Cytokine-cytokine interactions and the brain. Brain Res Bull 2000, 51:3-9.
51. Vitkovic L, Konsman JP, Bockaert J, et al.: Cytokine signals propagate through the brain. Mol Psychiatry 2000, 5:604-615.
52. Rivest S: Molecular insights on the cerebral innate immune system. Brain Behav Immun 2003, 17:13-19.
53. Turnbull AV, Rivier C: Regulation of the HPA axis by cytokines. Brain Behav Immun 1995, 9:253-275.
54. Tonelli LH, Postolache TT, Sternberg EM: Inflammatory genes and neural activity: Involvement of immune genes in synaptic function and behavior. Front Biosci 2005, 10:675-680.
55. Quan N, Zhang Z, Demetrikopoulos MK: Evidence for involvement of B lymphocytes in the surveillance of lung metastasis in the rat. Cancer Res 1999, 59:1080-1089.
56. Tonelli LH, Maeda S, Rapp KL, et al.: Differential induction of interleukin-I beta mRNA in the brain parenchyma of Lewis and Fischer rats after peripheral injection of lipopolysaccharides. J Neuroimmunol 2003, 140:126-136.
57. Tonelli LH, Postolache TT: Tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and major histocompatibility complex molecules in the normal brain and after peripheral immune challenge. Neurol Res 2005, 27:679-684.
58. Singareddy RK, Balon R: Sleep and suicide in psychiatric patients. Ann Clin Psychiatry 2001, 13:93-101.
59. Fawcett J, Scheftner WA, Fogg L, et al.: Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990, 147:1189-1194.
60. Krueger JM, Walter J, Dinarello CA, et al.: Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol 1984, 246:R994-R999.
61. Opp MR, Krueger JM: Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever. Am J Physiol 1991, 260:R453-R457.
62. Kapas L, Krueger JM: Tumor necrosis factor-beta induces sleep, fever, and anorexia. Am J Physiol 1992, 263:R703-R707.
63. Gemma C, Imeri L, de Simoni MG, et al.: Interleukin-1 induces changes in sleep, brain temperature, and serotonergic metabolism. Am J Physiol 1997, 272:R601-R606.
64. Hogan D, Morrow JD, Smith EM, et al.: Interleukin-6 alters sleep of rats. J Neuroimmunol 2003, 137:59-66.
65. Kushikata T, Fang J, Wang Y, Krueger JM: Interleukin-4 inhibits spontaneous sleep in rabbits. Am J Physiol 1998, 275:R1185-R1191.
66. Kushikata T, Fang J, Krueger JM: Interleukin-10 inhibits spontaneous sleep. J Interferon Cytokine Res 1999, 19:1025-1030.
67. Vgontzas AN, Chrousos GP: Sleep, the hypothalamicpituitary-adrenal axis, and cytokines: Multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin North Am 2002, 31:15-36.
68. Hughes K, Glass C, Ripchinski M, et al.: Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 2003, 58:380-385.
69. Hamano N, Terada N, Maesako K, et al.: Effect of sex hormones on eosinophilic inflammation in nasal mucosa. Allergy Asthma Proc 1998, 19:263-269.
70. Vliagoftis H, Dimitriadou V, Boucher W, et al.: Estradiol augments while tamoxifen inhibits rat mast cell secretion. Int Arch Allergy Immunol 1992, 98:398-409.
71. Osman M: Therapeutic implications of sex differences in asthma and atopy. Arch Dis Child 2003, 88:587-590.
72. Illum L: Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004, 56:3-17.
73. Thorne RG, Pronk GJ, Padmanabhan V: Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127:481-496.
74. Mori I, Goshima F, Ito H, et al.: The vomeronasal chemosensory system as a route of neuroinvasion by herpes simplex virus. Virology 2005, 334:51-58.
75. Loftus LT, Li HF, Gray AJ, et al.: In vivo protein transduction to the CNS. Neuroscience 2006, 139:1061-1067.
76. Kalueff AV, Lehtimaki KA, Ylinen A, et al.: Intranasal administration of human IL-6 increases the severity of chemically induced seizures in rats. Neurosci Lett 2004, 365:106-110.
77. Pelidou SH, Zou LP, Deretzi G, et al.: Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role. Exp Neurol 2000, 163:165-172.
78. Annesi-Maesano I: Epidemiological evidence of the occurrence of rhinitis and sinusitis in asthmatics. Allergy 1999, 54(Suppl 57):7-13.
79. Dykewicz MS, Fineman S, Skoner DP, et al.: Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998, 81:478-518.
80. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998, 351:1225-1232.
81. Bousquet J, Van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108(5 Suppl):S147-S334.
82. Dykewicz MS: Rhinitis and sinusitis. J Allergy Clin Immunol 2003, 111(2 Suppl):S520-S529.
83. Demoly P, Allaert FA, Lecasble M, Bousquet J: Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003, 58:672-675.
84. Ku M, Silverman B, Prifti N, et al.: Prevalence of migraine headaches in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006, 97:226-230.
85. Low NC, Merikangas KR: The comorbidity of migraine. CNS Spectr 2003, 8:433-434, 437-444.
86. Frediani T, Lucarelli S, Pelliccia A, et al.: Allergy and childhood epilepsy: A close relationship? Acta Neurol Scand 2001, 104:349-352.
87. Theoharides TC, Donelan J, Kandere-Grzybowska, et al.: The role of mast cells in migraine pathophysiology. Brain Res Rev 2005, 49:65-76.
88. Boyce JA; Mast cells: Beyond IgE. J Allergy Clin Immunol 2003, 111:24-32.
89. Berger WE: TAeatment update: allergic rhinitis. Allergy Asthma Proc 2001, 22:191-198.
90. Borish L: AllSrgic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol 2003, 112:1021-1031.
91. Hamilton RG, Adkinson NF Jr.: Clinical laboratory assessment of IgE-dependent hypersensitivity. J Allergy Clin Immunol 2003, 111(2 Suppl):S687-S701.
92. Tomooka LT, Murphy C, Davidson TM: Clinical study and literature review of nasal irrigation. Laryngoscope 2000, 110:1189-1193.
93. Weiner JM, Abramson MJ, Puy RM: Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 1998, 317:1624-1629.
94. Yáñez A, Rodrigo GJ: Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002, 89:479-484.
95. Rodrigo GJ, Yáñez A: The role of antileukotriene therapy in seasonal allergic rhinitis: A systematic review of randomized trials. Ann Allergy Asthma Immunol 2006, 96:779-786.
96. Chait LD: Factors influencing the reinforcing and subjective effects of ephedrine in humans. Psychopharmacology (Berl) 1994, 113:381-387.
97. Meltzer EO, Weiler JM, Widlitz MD: Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996, 97:617-626.
98. US Food and Drug Administration: Early communication about an ongoing safety review of montelukast (Singulair). March 27, 2008. Available at http://www.fda.gov/cder/drug/early_comm/montelukast.htm
99. Brozek JL, Baena-Cagnani CE, Bonini S, et al.: Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy 2008, 63:38-46.
100. Calderon MA, Alves B, Jacobson M, et al.: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, CD001936.
101. Radulovic S, Calderon MA, Wilson DR, et al.: Safety profile of sublingual immunotherapy (SLIT) for allergic rhinitis (AR). J Allergy Clin Immun 2008, 121:S142.
102. Didier A, Malling H, Worm M, et al.: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120:1338-1345.
103. Kaliner MA: Omalizumab and the treatment of allergic rhinitis. Curr Allergy Asthma Rep 2004, 4:237-244.